Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice

相似书籍

• N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
  由: Baek, R, et al.
  出版: (2008)
• N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
  由: Baek, R, et al.
  出版: (2004)
• Substrate deprivation therapy reduces brain ganglioside content and GM1 in neonatal storage disease mice
  由: Kasperzyk, J, et al.
  出版: (2002)
• "Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice" (vol 46, pg 744, 2004)
  由: Kasperzyk, J, et al.
  出版: (2005)
• N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
  由: Kasperzyk, J, et al.
  出版: (2004)